1. Inicio
  2. Publicaciones
  3. Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Grupos

Abstract

Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves' orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression. Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.

Datos de la publicación

ISSN/ISSNe:
0167-6830, 1744-5108

Orbit-The International Journal on Orbital Disorders-Oculoplastic and Lacrimal Surgery  TAYLOR & FRANCIS INC

Tipo:
Article
Páginas:
1-4
PubMed:
29420104
Factor de Impacto:
0,247 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 12

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Decompression; Graves' orbitopathy; dysthyroid optic neuropathy; steroids; tocilizumab

Compartir